Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonists.
Morriello GJ, Wendt HR, Bansal A, Di Salvo J, Feighner S, He J, Hurley AL, Hreniuk DL, Salituro GM, Reddy MV, Galloway SM, McGettigan KK, Laws G, McKnight C, Doss GA, Tsou NN, Black RM, Morris J, Ball RG, Sanfiz AT, Streckfuss E, Struthers M, Edmondson SD. Morriello GJ, et al. Among authors: galloway sm. Bioorg Med Chem Lett. 2011 Mar 15;21(6):1865-70. doi: 10.1016/j.bmcl.2010.12.087. Epub 2010 Dec 25. Bioorg Med Chem Lett. 2011. PMID: 21353541
Potentially mutagenic impurities: analysis of structural classes and carcinogenic potencies of chemical intermediates in pharmaceutical syntheses supports alternative methods to the default TTC for calculating safe levels of impurities.
Galloway SM, Vijayaraj Reddy M, McGettigan K, Gealy R, Bercu J. Galloway SM, et al. Regul Toxicol Pharmacol. 2013 Aug;66(3):326-35. doi: 10.1016/j.yrtph.2013.05.005. Epub 2013 May 17. Regul Toxicol Pharmacol. 2013. PMID: 23688841
Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.
Ellis JM, Altman MD, Bass A, Butcher JW, Byford AJ, Donofrio A, Galloway S, Haidle AM, Jewell J, Kelly N, Leccese EK, Lee S, Maddess M, Miller JR, Moy LY, Osimboni E, Otte RD, Reddy MV, Spencer K, Sun B, Vincent SH, Ward GJ, Woo GH, Yang C, Houshyar H, Northrup AB. Ellis JM, et al. J Med Chem. 2015 Feb 26;58(4):1929-39. doi: 10.1021/jm5018169. Epub 2015 Feb 16. J Med Chem. 2015. PMID: 25625541
Bacterial mutagenicity screening in the pharmaceutical industry.
Escobar PA, Kemper RA, Tarca J, Nicolette J, Kenyon M, Glowienke S, Sawant SG, Christensen J, Johnson TE, McKnight C, Ward G, Galloway SM, Custer L, Gocke E, O'Donovan MR, Braun K, Snyder RD, Mahadevan B. Escobar PA, et al. Among authors: galloway sm. Mutat Res. 2013 Apr-Jun;752(2):99-118. doi: 10.1016/j.mrrev.2012.12.002. Epub 2012 Dec 20. Mutat Res. 2013. PMID: 23262374 Review.
Corrigendum to "Bacterial mutagenicity screening in the pharmaceutical industry" [Mutat. Res. 752(2) (2013) 99-118].
Escobar PA, Kemper RA, Tarca J, Nicolette J, Kenyon M, Glowienke S, Sawant SG, Christensen J, Johnson TE, McKnight C, Ward G, Galloway SM, Custer L, Gocke E, O'Donovan MR, Braun K, Snyder RD, Mahadevan B. Escobar PA, et al. Among authors: galloway sm. Mutat Res. 2013 Oct-Dec;753(2):155. doi: 10.1016/j.mrrev.2013.09.003. Epub 2013 Oct 4. Mutat Res. 2013. PMID: 33348475 No abstract available.
Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides.
Bercu JP, Galloway SM, Parris P, Teasdale A, Masuda-Herrera M, Dobo K, Heard P, Kenyon M, Nicolette J, Vock E, Ku W, Harvey J, White A, Glowienke S, Martin EA, Custer L, Jolly RA, Thybaud V. Bercu JP, et al. Among authors: galloway sm. Regul Toxicol Pharmacol. 2018 Apr;94:172-182. doi: 10.1016/j.yrtph.2018.02.001. Epub 2018 Feb 9. Regul Toxicol Pharmacol. 2018. PMID: 29408293
A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
Müller L, Mauthe RJ, Riley CM, Andino MM, Antonis DD, Beels C, DeGeorge J, De Knaep AG, Ellison D, Fagerland JA, Frank R, Fritschel B, Galloway S, Harpur E, Humfrey CD, Jacks AS, Jagota N, Mackinnon J, Mohan G, Ness DK, O'Donovan MR, Smith MD, Vudathala G, Yotti L. Müller L, et al. Regul Toxicol Pharmacol. 2006 Apr;44(3):198-211. doi: 10.1016/j.yrtph.2005.12.001. Epub 2006 Jan 18. Regul Toxicol Pharmacol. 2006. PMID: 16412543
172 results